≡

Multiplex Assay Kit for EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. by FLIA (Flow Luminescence Immunoassay)

ZNEU1; MEGF7; Zneu1; Vascular endothelial statin; EGF Like Domain Containing 7; Epidermal growth factor-like protein 7; Multiple epidermal growth factor-like domains protein 7

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 85-103 91
EDTA plasma(n=5) 78-98 90
heparin plasma(n=5) 93-101 96
sodium citrate plasma(n=5) 85-97 91

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 97-104% 89-103% 79-101% 96-104%
EDTA plasma(n=5) 85-101% 93-105% 87-95% 99-105%
heparin plasma(n=5) 84-95% 81-99% 78-91% 96-104%
sodium citrate plasma(n=5) 98-105% 78-102% 95-104% 78-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:EGFL7) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Scientific Reports Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab PMC5443778
Scientific Reports Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. pubmed:28539619
International Journal of Clinical and Experimental Pathology EGF like domain multiple 7 regulates the migration and invasion of prostate cancer cells ISSN:1936-2625
Cancer Drug Resist MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPL643Mu01 Recombinant EGF Like Domain Protein, Multiple 7 (EGFL7) Positive Control; Immunogen; SDS-PAGE; WB.
RPL643Mu02 Recombinant EGF Like Domain Protein, Multiple 7 (EGFL7) Positive Control; Immunogen; SDS-PAGE; WB.
PAL643Mu02 Polyclonal Antibody to EGF Like Domain Protein, Multiple 7 (EGFL7) WB; IHC; ICC; IP.
PAL643Mu01 Polyclonal Antibody to EGF Like Domain Protein, Multiple 7 (EGFL7) WB; IHC; ICC; IP.
SEL643Mu ELISA Kit for EGF Like Domain Protein, Multiple 7 (EGFL7) Enzyme-linked immunosorbent assay for Antigen Detection.
LML643Mu Multiplex Assay Kit for EGF Like Domain Protein, Multiple 7 (EGFL7) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.